New investigational therapies for gastroesophageal reflux disease.
Although PPI have revolutionized the treatment of GERD and its complications, many patients continue to have breakthrough symptoms and take antacids and H2RA. Furthermore, acid reflux actually is the innocent bystander, with few drugs available to target the true culprit, a dysfunctional LES. Future development of treatments, such as the GABA(B) agonists, which reduce TLESR, may prove an important advance in the therapy of GERD by controlling acid and nonacid reflux better. The chemical, pharmacodynamic, and clinical limitations of PPI may be addressed by the development of innovative drugs, such as the P-CAB or gastrin vaccine, to control acid secretion. Which of these drugs, if any, will be the new GERD drug for the millennium is unknown. There is no question, however, that improved drug treatments will parallel a better understanding of the complicated pathophysiology of GERD.
Richter
Joel E
JE
Department of Medicine, Temple University School of Medicine, 3401 North Broad Street, 8th Floor, Parkinson Pavilion, Philadelphia, PA, 19140, USA. jrichter@temple.edu
D015507:Drugs, Investigational / Q000627:therapeutic use*; D004943:Esophagogastric Junction / Q000187:drug effects*; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D005745:Gastric Acidity Determination; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D035703:Therapies, Investigational / Q000379:methods*; D016896:Treatment Outcome
D015507:Drugs, Investigational